Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2015 1
2016 2
2017 3
2018 4
2019 3
2020 3
2021 3
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.
Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Klatte T, Kuusk T, Lam TB, Marconi L, Powles T, Tahbaz R, Volpe A, Bex A. Ljungberg B, et al. Among authors: tahbaz r. Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26. Eur Urol. 2022. PMID: 35346519 Free article.
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.
Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Ljungberg B, Marconi L, Klatte T, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Powles T, Bex A. Bedke J, et al. Among authors: tahbaz r. Eur Urol. 2023 Jan;83(1):10-14. doi: 10.1016/j.eururo.2022.10.010. Epub 2022 Oct 27. Eur Urol. 2023. PMID: 36511268
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel.
Capitanio U, Bedke J, Albiges L, Volpe A, Giles RH, Hora M, Marconi L, Klatte T, Abu-Ghanem Y, Dabestani S, Fernández Pello S, Hofmann F, Kuusk T, Tahbaz R, Powles T, Ljungberg B, Bex A. Capitanio U, et al. Among authors: tahbaz r. Eur Urol. 2023 Jan;83(1):3-5. doi: 10.1016/j.eururo.2022.09.026. Epub 2022 Oct 15. Eur Urol. 2023. PMID: 36253306
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View.
Hora M, Albiges L, Bedke J, Campi R, Capitanio U, Giles RH, Ljungberg B, Marconi L, Klatte T, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Powles T, Bex A, Trpkov K. Hora M, et al. Among authors: tahbaz r. Eur Urol. 2023 Feb;83(2):97-100. doi: 10.1016/j.eururo.2022.11.001. Epub 2022 Nov 23. Eur Urol. 2023. PMID: 36435661
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L, Klatte T, Volpe A, Abu-Ghanem Y, Dabestani S, Pello SF, Hofmann F, Kuusk T, Tahbaz R, Powles T, Bex A. Bedke J, et al. Among authors: tahbaz r. Eur Urol. 2021 Oct;80(4):393-397. doi: 10.1016/j.eururo.2021.04.042. Epub 2021 May 29. Eur Urol. 2021. PMID: 34074559
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A. Fernández-Pello S, et al. Among authors: tahbaz r. Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8. Eur Urol. 2017. PMID: 27939075 Review.
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.
Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L, Klatte T, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Powles T, Bex A. Bedke J, et al. Among authors: tahbaz r. Eur Urol. 2022 Feb;81(2):134-137. doi: 10.1016/j.eururo.2021.11.022. Epub 2021 Dec 15. Eur Urol. 2022. PMID: 34920897
22 results